ClinicalTrials.gg
CompletedNCT07193563Updated Apr 8, 2026

A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder

A Phase 2 interventional study of ENX-102 and Placebo in Social Anxiety Disorder (SAD), sponsored by Engrail Therapeutics INC. Completed at 20 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Engrail Therapeutics INC · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies in Phobia, Social with a site in United States — 23 open to participants now, 29 under way, 1 of them phase 3. Phobia, Social · United States.

Enrollment
122nd of 178
47 · median 64
Started
2025
with 11 others
Phase 2
25 of 187
2 open now
Registered
178th of 187
by date

Among the 187 studies in Phobia, Social with a site in United States, this one is the 122nd largest by enrollment of the 178 interventional ones that give a count, is one of 12 that started in 2025, is one of 25 in phase 2, and was the 178th registered.

Phobia, Social

368 studies on the registry are indexed under Phobia, Social; 59 are open to participants now.

Browse Phobia, Social studies →

Open to participants now

23 of the 187 studies in Phobia, Social with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Phobia, Social studies recruiting now, 10 (22%) set no upper age limit and 34 (74%) stop at 75 or younger; 14 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Phobia, Social with a site in United States, or all of them as a file.
02

Study summary

This is a double-blind study to evaluate the efficacy and safety of ENX-102 in participants with social anxiety disorder (SAD).

03

Conditions studied

  • Social Anxiety Disorder (SAD)

Browse trials for

Keywords

  • Social Anxiety
  • ENX-102
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female at birth, aged 18-70 years, inclusive, at screening Diagnosed with SAD according to the , Fifth Edition, Text Revision (DSM-5-TR), confirmed by a Mini-International Neuropsychiatric Interview (MINI) version 7.0.2
  • LSAS total score of ≥70
  • CGI-S score of ≥4

Key Exclusion Criteria:

  • Clinically predominant psychiatric diagnosis other than SAD per the MINI
  • Any past/lifetime or current diagnosis of a neurocognitive disorder or psychotic disorder, or any current diagnosis of posttraumatic stress disorder, obsessive compulsive disorder, or bipolar disorder
  • Reports moderately severe to severe symptoms of depression
  • Frequent use of benzodiazepines within 90 days of screening
  • Used prohibited medication or prohibited herbal or other supplements within 5 half- lives or 21 days prior to Day 1 and unwillingness to refrain from their use for the duration of the trial
  • Recent suicidal ideation or behavior
  • Current or recent moderate or severe substance use disorder as assessed by the MINI
  • Is unwilling/unable to abstain from alcohol, marijuana, THC, CBD, and/or any other psychoactive substances (except for nicotine or caffeine) for the duration of the trial, per Investigator judgment, and/or has a positive alcohol test or drug test at Screening or Day 1
  • abnormal findings in safety assessments
  • Has significant progressive disorders or unstable medical conditions Unable to comply with the requirements of the study or, in the opinion of the Investigator or Sponsor, is unsuitable for the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    ENX-102

    Participants will receive 2 mg of ENX-102 in capsule form orally once daily for 6 weeks, followed by 2 weeks of tapered dose and up to 2 weeks of placebo in capsule form before and/or after the 8-week ENX-102 treatment period.

    Drug: ENX-102

  • Placebo comparator
    Placebo

    Participants will receive ENX-102 matching placebo in capsule once daily for 10 weeks

    Other: Placebo

Interventions

  • oral capsule

  • OtherPlacebo

    oral capsule

06

What researchers measure

Primary outcomes

  1. Change From Baseline on the Clinician-administered Liebowitz Social Anxiety Scale (LSAS) - Total score

    The LSAS is a 24-item semi-structured interview measure of fear and avoidance experienced in a range of social and performance situations. The 24 items are divided into 2 subscales, 13 concerning performance anxiety \& 11 pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations (0=none, 1=mild, 2=moderate, 3= severe), and then the same items are rated regarding avoidance of the situation (0=never, 1=occasionally, 2=often, 3=usually). An overall global score (0 to 144) is calculated by adding total fear/anxiety and total avoidance scores. Higher scores indicated higher probability of social anxiety disorder.

    Time frame: Baseline (Day 1) and Week 6

07

Study locations

20 sites
  • IMA Clinical Research Phoenix
    Phoenix, Arizona 85012, United States
  • University of California
    La Jolla, California 92037, United States
  • Neuroresearch Group
    Los Angeles, California 90025, United States
  • Excell Research, Inc.
    Oceanside, California 92056, United States
  • Anderson Clinical Research
    Redlands, California 92374, United States
  • California Neuroscience Research, LLC
    Sherman Oaks, California 91403, United States
  • Sunwise Clincial Research
    Walnut Creek, California 94596, United States
  • Mountain View Clinical Research
    Denver, Colorado 80209, United States
  • CNS Health
    Jacksonville, Florida 32256, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • CenExel iResearch, LLC
    Savannah, Georgia 31405, United States
  • IMA Clinical Research
    Las Vegas, Nevada 89102, United States
  • Redbird Research
    Las Vegas, Nevada 89119, United States
  • Cenexel HRI
    Berlin, New Jersey 08009, United States
  • SPRI Clinical Trials, LLC
    Brooklyn, New York 11235, United States
  • Neurobehavioral Research, Inc.
    Cedarhurst, New York 11516, United States
  • Clinical Neurosciences, Inc
    Memphis, Tennessee 38119, United States
  • Austin Clinical Trials Partners
    Austin, Texas 78737, United States
  • Grayline Research Center
    Wichita Falls, Texas 76309, United States
  • Core Clinical Research
    Everett, Washington 98201, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Mar 2026, 6 months.

Of 15 phase 2 interventional studies under Phobia, Social, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Sep 26, 2025
StartActual
Sep 5, 2025
Primary completionActual
Mar 19, 2026
CompletionActual
Mar 19, 2026
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07193563
Lead sponsor
Engrail Therapeutics INC
Responsible party
Sponsor
First posted
Sep 26, 2025
Start date
Sep 5, 2025
Primary completion
Mar 19, 2026
Completion
Mar 19, 2026
Last update
Apr 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ENX-102

Start the discussion